Ipamorelin’s five-residue linear peptide sequence delivers unique receptor selectivity unavailable to non-selective GHRP agonists like GHRP-2 and GHRP-6:
- Short linear pentapeptide backbone engineered for exclusive binding to pituitary somatotroph GHSR subtype 1a, eliminating cross-activation of hypothalamic corticotroph and lactotroph cell populations.
- Minimal off-target endocrine stimulation: unlike GHRP-6/GHRP-2, Ipamorelin does not induce dose-dependent ACTH or prolactin elevation in mammalian preclinical models, creating a pure growth hormone research tool isolated from secondary endocrine pathway interference.
- C-terminal amidation enhances serum proteolytic stability, extending measurable systemic GH secretagogue activity in rodent and primate endocrine cohort studies.
- Balanced short circulating half-life supports frequent-dosing growth hormone kinetic research, ideal for comparative GH secretion curve assays against long-acting CJC-1295 DAC peptides.
| Property | Value |
|---|---|
| Full Name | Ipamorelin, Selective GHSR Growth Hormone Secretagogue Pentapeptide |
| CAS Registry Number | 170714-78-0 |
| Molecular formula | C38H49N9O5 |
| Molecular weight | 711.86 g/mol |
| Peptide length | 5 amino acid pentapeptide |
| Compound class | Synthetic selective ghrelin/GHSR agonist growth hormone secretagogue |
| Primary molecular target | Pituitary somatotroph GHSR-1a receptor (exclusive GH secretion) |
| Secondary off-target activity | No measurable ACTH/prolactin stimulation at research doses |
| Physical form | White crystalline lyophilised powder |
| Solubility | Sterile bacteriostatic water, neutral PBS pH7.0–7.4 |
| Purity standard | ≥99% HPLC confirmed per batch COA |
| Standard IP-series stock sizes | IP5 (5mg), IP10 (10mg) |
Ipamorelin’s selective growth hormone secretagogue profile is documented across hundreds of peer-reviewed pituitary endocrinology, body composition and metabolism laboratory publications spanning 25 years of GHSR peptide research. Core experimental models include primary pituitary cell culture GH secretion assays, rodent lean mass/visceral fat body composition tracking and comparative GH-axis agonist dose-response curve trials.
Original Ipamorelin discovery research by the Deghenghi peptide laboratory group identified the pentapeptide’s unique single-target somatotroph selectivity, contrasting against multi-target GHRP agonists that co-stimulate adrenal and lactotrophic endocrine pathways. Follow-up primate endocrine cohort publications validated consistent dose-dependent growth hormone pulsatile release without secondary ACTH spikes, establishing Ipamorelin as the gold-standard control compound for pure GH signaling comparative research.
Ipamorelin is the most common combinatorial pairing with CJC-1295 (with or without DAC) for synergistic growth hormone axis research, combining short-acting GHSR stimulation and long-acting GHRH agonist activity to amplify pulsatile GH secretion in preclinical models. Zypep Peptides supplies standalone IP10 vials alongside CD/CND-series CJC-1295 vials for dual GH secretagogue experimental design.
Zypep Peptides manufactures factory-direct bulk Ipamorelin lyophilized powder for university endocrinology labs, sports metabolism preclinical CROs and global peptide wholesale distributors. Request bulk volume pricing, full batch test COA and refrigerated international shipping terms via the website floating chat dialog on zypep.com. All IP-series products marked FOR LABORATORY ENDOCRINE RESEARCH USE ONLY, not intended for human therapeutic administration.
Reviews
There are no reviews yet.